Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 10;6(4):00451-2020.
doi: 10.1183/23120541.00451-2020. eCollection 2020 Oct.

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

Alexandra M Nanzer  1   2 , Jaideep Dhariwal  1 , Joanne Kavanagh  1   2 , Andrew Hearn  1   2 , Mariana Fernandes  1 , Louise Thomson  1 , Cris Roxas  1 , Linda Green  1 , Grainne D'Ancona  1 , Sangita Agarwal  3 , Brian D Kent  1 , David J Jackson  1   2
Affiliations

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

Alexandra M Nanzer et al. ERJ Open Res. .

Abstract

Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures https://bit.ly/2GI0vhf.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.M. Nanzer reports personal fees from AstraZeneca and Napp outside the submitted work. Conflict of interest: J. Dhariwal has nothing to disclose. Conflict of interest: J. Kavanagh has nothing to disclose. Conflict of interest: A. Hearn has nothing to disclose. Conflict of interest: M. Fernandes has nothing to disclose. Conflict of interest: L. Thomson has nothing to disclose. Conflict of interest: C. Roxas has nothing to disclose. Conflict of interest: L. Green has nothing to disclose. Conflict of interest: G. D'Ancona reports personal fees from Chiesi, AstraZeneca, GSK and Napp outside the submitted work. Conflict of interest: S Agarwal has nothing to disclose. Conflict of interest: B.D. Kent reports personal fees from AstraZeneca and GSK outside the submitted work. Conflict of interest: D.J. Jackson reports personal fees from AstraZeneca, GSK, Teva, Sanofi and Novartis outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Reduction from baseline to 48 weeks in a) maintenance oral corticosteroid (mOCS) dose (p=0.0018), b) Birmingham Vasculitis Activity Score (BVAS) (p=0.0007) and c) Asthma Control Questionnaire score (ACQ) (p=0.012). Data are presented as a) median (interquartile range) and b and c) mean±sd.
See this image and copyright information in PMC

References

    1. Comarmond C, Pagnoux C, Khellaf M, et al. . Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65: 270–281. doi:10.1002/art.37721 - DOI - PubMed
    1. Lefebvre P, Robitaille MN, Albers F, et al. . Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin 2017; 33: 57–65. doi:10.1080/03007995.2016.1233101 - DOI - PubMed
    1. Puechal X, Pagnoux C, Baron G, et al. . Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology (Oxford) 2019; 58: 2107–2116. doi:10.1093/rheumatology/kez139 - DOI - PubMed
    1. Wechsler ME, Akuthota P, Jayne D, et al. . Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017; 376: 1921–1932. doi:10.1056/NEJMoa1702079 - DOI - PMC - PubMed
    1. Kent BD, d'Ancona G, Fernandes M, et al. . Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res 2020; 6: 00311-2019. - PMC - PubMed

LinkOut - more resources